Cullinan Therapeutics Inc.
- Address
- 1 Main Street Suite 1350
Sponsor Overview
Specializations
Autoimmune Rheumatic Diseases
Research activity is centered on systemic lupus erythematosus and treatment-refractory rheumatoid arthritis, with a strong focus on immune-mediated joint and systemic inflammation.
- Systemic lupus erythematosus
- Treatment-refractory rheumatoid arthritis
- Autoimmune disease
These studies reflect interest in difficult-to-treat inflammatory conditions affecting multiple organ systems and chronic musculoskeletal disease.
Exocrine and Glandular Autoimmunity
The sponsor is also involved in research on Sjogren's disease, a condition marked by autoimmune involvement of the salivary and lacrimal glands.
- Sjogren's disease
- Glandular inflammation
- Dry eye and dry mouth syndromes
This area highlights therapeutic interest in disorders affecting secretory function and mucosal comfort.
Immune-Modulating Therapeutics
Clinical work is organized around immune-targeted therapy for chronic autoimmune disease, with attention to biologically driven interventions in inflammatory pathology.
- Immune modulation
- Inflammatory pathways
- Biologic therapy
The sponsor’s portfolio reflects therapeutic interest in conditions where immune dysregulation is central to disease burden.
Specialty Autoimmune Medicine
Its funded studies span rheumatology and related systemic autoimmune disorders, areas that require focused management of persistent immune activation and tissue injury.
- Rheumatology
- Systemic autoimmune disorders
- Chronic inflammatory disease
The clinical landscape emphasizes conditions with ongoing unmet need in specialist autoimmune care.
Multinational Clinical Development in Autoimmunity
Research is being conducted across multiple international sites, supporting studies in autoimmune disease populations with broad geographic reach.
- International trial network
- Autoimmune clinical research
- Specialist study sites
The sponsor’s active portfolio is concentrated in therapeutic areas where precise immunologic intervention is a central medical need.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Phase 1b Open-Label Study to Evaluate the Safety and Efficacy of CLN-978 in Patients with Moderate to Severe Systemic Lupus Erythematosus |  Bulgaria France Germany Poland Romania Spain | Recruiting |
| Phase 1b Open-Label Evaluation of CLN-978 in Patients with Active Moderate to Severe Sjogren's Disease | France Germany Italy Poland | Recruiting |
| Phase I Open-Label Evaluation of CLN-978 in Patients with Treatment-Refractory Rheumatoid Arthritis | Germany Italy Poland | Recruiting |
Data & Insights
This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 20 sites across their trial portfolio.
Therapeutic Focus
- 1.Musculoskeletal Diseases2 trials238 other sponsors
- 2.Immune System Diseases1 trial322 other sponsors
Partnered Research Centres
20 centres- Address
- Intrarea Tudor Stefan 38-40, 011658 Bucharest
- Address
- Piazza Luigi Miraglia 2, 80138 Naples
- Address
- Ul. Nadwislanska 37, 05-410 Jozefow
- Address
- Boulevard Tanguy Prigent, 29200 Brest
- Address
- 1 Place Alexis Ricordeau, 44000 Nantes
- Address
- Largo Francesco Vito 1, 00168 Rome
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Cullinan Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.